Along these lines, a recent study showed that BRCA 1 and 2 mutated ovarian tumors are characterized by increased neoantigen load and that this correlates with increased number of TILs, increased expression of PD1 and PDL1, and is linked to improved clinical outcome [152]. The gene discussed is CD274; the disease is ovarian neoplasm.